Premium
Activation of cyclophosphamide in man and animals
Author(s) -
Brock N.,
Gross R.,
Hohorst H.J.,
Klein H. O.,
Schneider B.
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197106)27:6<1512::aid-cncr2820270636>3.0.co;2-q
Subject(s) - cyclophosphamide , metabolite , active metabolite , medicine , pharmacology , in vivo , distribution (mathematics) , endocrinology , chemistry , chemotherapy , biology , mathematical analysis , microbiology and biotechnology , mathematics
The authors studied the alkylating activity in the blood serum of man and rats after administration of cyclophosphamide, and its dependence on dosage. The alkylating activity was determined by means of the NBP test. For the process of activation, distribution in the body, and elimination, a mathematic model was developed and checked by means of the experimental data. The following results were obtained: 1. The cyclophosphamide activation curves studied for the doses of 15.6, 31.3, and 62.5 mg/kg are very constant in the rat, the NBP regression lines depending clearly on dosage. 2. The pharmacokietics of the metabolite level in man, studied for the doses of 30 and 60 mg/kg, show great individual fluctuations. But even here the dependence of the activity curves on dosage is statistically significant. 3. The average peaks of the metabolite level in man, related to the same dose, are about half to three quarters those found in the rat. 4. In man, the alkylating activity in the blood is detectable longer than in the rat. The values of the elimination constants in man are about two thirds of those in the rat. 5. Direct determination of the cyclophosphamide activation rate in liver sections of man and rats shows the activation rate in man related to the moist weight of the liver, to be‐even in vitro‐only about 60% of that of the rat. 6. Our findings show that there are no basic qualitative differences in cyclophosphamide activation between man and rat. They offer interesting aspects for the improvement of the therapeutic use of cyclophosphamide.